Why Farbe Firma is the Top Manufacturer of Leuprolide Acetate Depot Injection
- Maulik Sudani
- 24 hours ago
- 10 min read
Last Updated: July 1, 2026
TL;DR: Leuprolide Acetate Depot Injection - a sterile, long-acting depot of leuprolide acetate, a synthetic nonapeptide GnRH (LHRH) agonist in which the peptide is encapsulated in biodegradable poly(lactide-co-glycolide) microspheres and supplied as a lyophilised powder reconstituted into an injectable suspension for intramuscular or subcutaneous use, commonly in 1-month, 3-month, 4-month and 6-month depot strengths - is the sustained-release hormonal therapy clinicians use for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty, where continuous GnRH-receptor stimulation suppresses testosterone or estradiol after an initial surge. Because a controlled-release peptide microsphere depot is one of the most complex parenteral dosage forms to make, each depot must deliver a sterile, correctly dosed product that releases the peptide steadily over its full labelled duration, with the peptide content and purity, the in-vitro release profile, the microsphere particle size and drug loading, residual solvents and moisture, resuspendability and syringeability, sterility, low endotoxin and verified container-closure integrity all mattering to safety and performance. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Leuprolide Acetate Depot Injection at our Gujarat, India facility and supplies it to oncology, urology, gynaecology and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: GnRH (LHRH) agonist, sustained-release depot - leuprolide acetate is a synthetic nonapeptide that, given continuously, suppresses pituitary LH and FSH and so lowers testosterone or estradiol, and Leuprolide Acetate Depot Injection (a peptide-microsphere depot given intramuscularly or subcutaneously in 1-, 3-, 4- and 6-month strengths) must release the peptide steadily across its full labelled duration.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, fully aseptic peptide-microsphere manufacture and lyophilisation with no terminal sterilisation, validated water-for-injection loops, control of peptide content and purity by RP-HPLC, the in-vitro release profile, microsphere particle size and drug loading, residual solvents and moisture, sterility and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, in-vitro release and microsphere-characterisation data, ICH Q3C residual-solvent data, aseptic-process-validation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile peptide-microsphere depot contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Leuprolide Acetate Depot Injection Demands a Premium Manufacturer
Leuprolide Acetate Depot Injection holds a central place in oncology, urology and gynaecology across every market. It is the therapy a clinician reaches for when a patient needs sustained suppression of sex-hormone production - in advanced prostate cancer, where lowering testosterone slows the disease; in endometriosis and in uterine fibroids, where lowering estradiol relieves symptoms and shrinks lesions; and in central precocious puberty, where halting premature hormonal signalling protects a child's development. Leuprolide acetate is a synthetic nonapeptide analogue of gonadotropin-releasing hormone: given continuously rather than in the body's natural pulses, it first briefly stimulates and then desensitises the pituitary GnRH receptors, so that luteinising hormone, follicle-stimulating hormone and, in turn, testosterone or estradiol fall to very low levels after an initial surge. What makes the product distinctive is not the peptide alone but the delivery system: rather than a daily injection, the depot encapsulates leuprolide in biodegradable polymer microspheres that release it slowly over one, three, four or even six months from a single administration. Because a single depot then governs a patient's hormonal therapy for months, every unit must be sterile, correctly dosed and, above all, must release the peptide at the intended rate over its full labelled duration, since the prescriber depends on a dependable, reproducible controlled-release depot.
That clinical reality places exceptional demands on the manufacturer. Leuprolide Acetate Depot Injection is presented as a sterile lyophilised microsphere powder that is reconstituted with a supplied diluent into an injectable suspension - for example a one-month or three-month intramuscular depot - so the peptide content must be exact and the dose delivered complete so that each depot provides the labelled amount of leuprolide. The defining challenge is that the therapeutic effect depends entirely on the controlled-release behaviour of the microspheres: the biodegradable poly(lactide-co-glycolide) polymer must release the peptide steadily as it hydrolyses, so the in-vitro release profile is a genuine critical quality attribute, and it is governed by the microsphere particle-size distribution, the drug loading and encapsulation efficiency, and the polymer's molecular weight and lactide-to-glycolide ratio. The peptide itself must be controlled for identity, content and purity by validated RP-HPLC, with peptide-related impurities such as deamidation and oxidation products held within limits. Because both the peptide and the polymer are heat- and hydrolysis-sensitive, the product cannot be terminally sterilised and must be made by a fully aseptic process throughout - aseptic microsphere formation, sterile filtration, aseptic filling and lyophilisation - under rigorous bioburden, endotoxin and media-fill control. The organic solvents used to form the microspheres must be controlled as residual solvents under ICH Q3C and verified by gas chromatography, and residual moisture in the lyophilised cake must be held low by Karl Fischer, since moisture accelerates polymer hydrolysis and peptide degradation. The finished depot must resuspend uniformly in its diluent and pass cleanly through the supplied needle, so resuspendability and syringeability are tested as part of dose delivery. Sterility, low endotoxin, particulate control and container-closure integrity complete the picture, and the label must carry the initial hormonal-surge or tumour-flare caution, the hypogonadal effects of prolonged therapy and the storage conditions of the particular presentation. Choosing a Leuprolide Acetate Depot Injection manufacturer that treats the in-vitro release profile, microsphere characterisation, aseptic processing and peptide-purity control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Leuprolide Acetate Depot Injection Manufacturer Apart
A world-class manufacturer of Leuprolide Acetate Depot Injection invests in three areas that weaker suppliers cannot match: precise, validated control of the peptide - identity, content and purity by RP-HPLC with peptide-related-impurity control - which a synthetic nonapeptide demands; complete mastery of the microsphere delivery system and its in-vitro release profile, which a controlled-release depot lives or dies by; and a fully aseptic, validated manufacturing and lyophilisation process, since a heat- and hydrolysis-sensitive peptide-polymer product can never be terminally sterilised. It starts with the inputs - pharmacopoeial-grade leuprolide acetate and the biodegradable poly(lactide-co-glycolide) polymer, each sourced from qualified, audited suppliers with full peptide-purity, molecular-weight and residual-monomer profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the entire value of the product is the ability to release a precise peptide dose steadily over months, the in-vitro release profile, the microsphere particle-size distribution, the drug loading and the encapsulation efficiency are treated as central evidence rather than supporting annexes, and every one of them is tied back to the polymer grade and the microsphere-forming process that produced it.
Manufacture then has to build the microspheres and defend both the peptide and the release profile. The leuprolide and the polymer are brought together and processed into microspheres of a controlled particle size - the peptide encapsulated within the biodegradable matrix - with the organic solvents then removed and the microspheres washed, collected, filled and lyophilised, every step carried out aseptically because there is no terminal sterilisation to fall back on. Sterile filtration of solutions, ISO Class 5 aseptic handling, validated aseptic-process simulations (media fills), and tight bioburden and endotoxin control run through the whole operation. Filled and freeze-dried units are inspected for cake appearance and defects; in-process and release testing confirm the peptide content and purity by RP-HPLC, the peptide-related-impurity profile, the in-vitro release profile against the approved specification, the microsphere particle-size distribution, the drug loading and encapsulation efficiency, residual organic solvents by gas chromatography under ICH Q3C, residual moisture by Karl Fischer, resuspendability in the supplied diluent, syringeability through the supplied needle, sub-visible particulate matter, bacterial endotoxin and sterility. Because the whole therapy depends on releasing the right dose at the right rate over months, the in-vitro release profile, the peptide purity, the particle-size distribution and the residual moisture are confirmed together, so the depot that leaves the plant carries the exact peptide load and the exact release behaviour the dossier specifies - releasing leuprolide steadily across its full labelled duration, with no dose dumping and no premature failure of the depot in the vial.
Quality Systems Behind Every Leuprolide Acetate Depot Injection
Every Farbe Firma Leuprolide Acetate Depot Injection batch is released only after a full stack of quality checks: stability-indicating RP-HPLC assay of leuprolide against reference standards, control of peptide-related impurities, the in-vitro release profile against the approved specification, microsphere particle-size distribution, drug loading and encapsulation efficiency, residual organic solvents by gas chromatography under ICH Q3C, residual moisture by Karl Fischer, resuspendability and syringeability, sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial or dual-chamber presentation. Certificates of analysis are issued with full traceability back to each leuprolide and polymer lot, the primary-packaging lot and the qualified person responsible for release. Because the product is made aseptically with no terminal sterilisation, the aseptic process is qualified through routine media fills and continuous environmental monitoring rather than assumed, and the in-vitro release profile is treated as the defining performance test of every batch.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated aseptic-processing and lyophilisation equipment, validated filling lines with 100 % inspection, controlled-environment weighing and microsphere handling, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because a controlled-release peptide microsphere depot is one of the most demanding parenteral dosage forms and the in-vitro release profile, peptide purity, particle-size distribution and residual moisture drive both efficacy and safety, we treat those attributes - together with sterility assurance - as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated conditions, with the in-vitro release profile, peptide purity, related impurities and residual moisture followed across the study, so the depot's dose and release behaviour stay within specification across the labelled shelf life, and the storage conditions on the label - controlled room temperature or refrigeration as the presentation requires, protected from moisture - are supported by real data rather than by assumption.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Leuprolide Acetate Depot Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including an expanding oncology, hormonal and long-acting-parenteral portfolio. For Leuprolide Acetate Depot Injection specifically, we supply the peptide-microsphere depot in 1-month, 3-month, 4-month and 6-month strengths in vial and dual-chamber or kit presentations under WHO-GMP conditions, with country-specific strengths, presentations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the peptide-purity, in-vitro-release, microsphere-characterisation, residual-solvent, aseptic-process-validation and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Leuprolide Acetate Depot Injection can request the in-vitro-release and stability summaries up front, which is often the deciding technical evidence for a controlled-release depot in hospital-formulary and ministry-of-health review, since it is precisely the release profile and the sterility assurance of an aseptically made peptide microsphere that separate a dependable depot from an unreliable one.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability data, in-vitro-release and microsphere-characterisation packages, ICH Q3C residual-solvent data, aseptic-process-validation and container-closure reports, translated package inserts and artwork - including intramuscular and subcutaneous administration and reconstitution instructions, the storage directions of the particular presentation, and the initial hormonal-surge or tumour-flare, hypogonadal-effect and pregnancy-exclusion cautions of the GnRH-agonist class - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics, including any cold-chain the presentation requires, to the destination market. When a buyer needs Leuprolide Acetate Depot Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the aseptic microsphere and lyophilisation suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through leuprolide and polymer sourcing, the design of a poly(lactide-co-glycolide) microsphere depot, the development and control of the in-vitro release profile, microsphere particle-size, drug-loading and encapsulation-efficiency control, residual-solvent and residual-moisture control, the aseptic-process and lyophilisation strategy for a product that can never be terminally sterilised, resuspendability and syringeability, sterility assurance, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a controlled-release peptide depot where the release profile, peptide purity and sterility assurance directly govern patient safety and the success of months of therapy, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Leuprolide Acetate Depot Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Leuprolide Acetate Depot Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, fully aseptic peptide-microsphere manufacture and lyophilisation with no terminal sterilisation, validated water-for-injection systems, routine media fills, 100 % inspection and continuous environmental monitoring.
Which strengths and presentations of Leuprolide Acetate Depot Injection do you supply?
Our peptide-microsphere depot is available in 1-month, 3-month, 4-month and 6-month strengths for intramuscular or subcutaneous use, supplied as a lyophilised microsphere powder with a diluent for reconstitution in vial and dual-chamber or kit presentations. Custom strengths, presentations, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Leuprolide Acetate Depot Injection mainly used for?
Leuprolide Acetate Depot Injection is used for conditions that respond to sustained suppression of sex hormones - advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty - because continuous GnRH-agonist stimulation lowers testosterone or estradiol after an initial surge. It is given as a single intramuscular or subcutaneous depot that releases the peptide over one to six months; Farbe Firma verifies the peptide content and purity, the in-vitro release profile, microsphere particle size, residual solvents and moisture, sterility and endotoxin at release so each depot is correctly dosed and releases as intended. The initial hormonal-surge or tumour-flare, hypogonadal-effect and pregnancy-exclusion cautions of the class are carried on the label.
Can Farbe Firma support country-specific registrations for Leuprolide Acetate Depot Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability data, in-vitro-release and microsphere-characterisation packages, ICH Q3C residual-solvent data, aseptic-process-validation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Leuprolide Acetate Depot Injection contract manufacturing?
MOQs vary by strength, depot duration, presentation, aseptic-process requirements, label complexity and dossier requirements. For our long-acting-parenteral and oncology presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments